The potential of long noncoding RNA therapies.

Autor: Mercer TR; Australian Institute for Biotechnology and Nanomaterials, University of Queensland, St Lucia, Australia. Electronic address: t.mercer@uq.edu.au., Munro T; Australian Institute for Biotechnology and Nanomaterials, University of Queensland, St Lucia, Australia., Mattick JS; School of Biotechnology and Biomolecular Biosciences, and University of New South Wales (UNSW) RNA Institute, UNSW Sydney, Sydney, Australia.
Jazyk: angličtina
Zdroj: Trends in pharmacological sciences [Trends Pharmacol Sci] 2022 Apr; Vol. 43 (4), pp. 269-280. Date of Electronic Publication: 2022 Feb 10.
DOI: 10.1016/j.tips.2022.01.008
Abstrakt: The human genome expresses vast numbers of long noncoding RNAs (lncRNA) that fulfil diverse roles in gene regulation, cell biology, development, and human disease. These roles are often mediated by sequence motifs and secondary structures bound by proteins and can regulate epigenetic, transcriptional, and translational pathways. These functional domains can be further optimised and engineered into RNA devices that are widely used in synthetic biology. We propose that natural lncRNA structures can be explored and exploited for the rational design and assembly of synthetic RNA therapies. This potential has been enabled by advances in the stability, immunogenicity, manufacture, and delivery of other RNA-based therapies, from which we can anticipate the pharmacological properties of lncRNA therapies that have not yet otherwise entered clinical trials.
(Crown Copyright © 2022. Published by Elsevier Ltd. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: